Form 4: Eton Pharmaceuticals Executive Sells Shares
Insider Transaction (Form 4)
David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc., sold 25,000 shares of common stock on August 24, 2026 for $65.07 per share.
Summary
- Option exercise/conversion: acquired 25,000 Common Stock at $7.31 ($182,750) on August 24, 2026; holds 62,025 after (Direct).
- Open-market sale: disposed of 25,000 Common Stock at $65.07 ($1,626,750) on August 24, 2026; holds 37,025 after (Direct).
- Option exercise/conversion: disposed of 25,000 Employee Stock Option on August 24, 2026; holds 70,000 after (Direct).
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $1,626,750 of stock on the open market.
Insider Transactions
David Krempa — Officer (Chief Business Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-24 | Option exercise/conversion | Common Stock | 25,000 | $7 | $182.8K | 62,025 |
| 2026-08-24 | Open-market sale | Common Stock | 25,000 | $65 | $1.6M | 37,025 |
| 2026-08-24 | Option exercise/conversion | Employee Stock Option | 25,000 | — | — | 70,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-24 | Option exercise/conversion (25,000 shares) |
| 2026-08-24 | Open-market sale (25,000 shares) |
| 2026-08-24 | Option exercise/conversion (25,000 shares) |
Keywords
insider transaction, Form 4, ETON, Eton Pharmaceuticals, Inc., bearish, David Krempa
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.